Eli Lilly and Co. and AstraZeneca have entered an agreement to co-develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor in development as a potential treatment for Alzheimer’s disease (AD).   The progression of AD is characterized by the accumulation of amyloid plaque in the brain, which is associated with the enzyme BACE. Inhibiting BACE is expected to prevent the formation of amyloid plaque and eventually slow the progression of the disease. AZD3293 h...